Want to see SION full AI Analyst Report?
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:42Neutral
Price Target:
$6.00
▼(-2.76% Downside)
Action:Reiterated
Date:08/11/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and rising cash burn) and bearish technical momentum (very low RSI and negative MACD). Valuation provides limited support due to a negative P/E and no dividend yield data. Corporate events add incremental risk after the Phase 2a miss and program discontinuation, partially offset by encouraging Phase 1 safety/PK results and strong cash resources.
Positive Factors
Low Leverage
Very low leverage and substantial equity provide financial flexibility during clinical development. This reduces debt-service pressure and gives Sionna more capacity to fund research, manage setbacks, and pursue strategic options.
Negative Factors
Pre-Revenue Model
Sionna has no product revenue and remains dependent on clinical progress before establishing a commercial business. Widening losses increase the importance of successful trials, regulatory advancement, and future financing or partnering.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage and substantial equity provide financial flexibility during clinical development. This reduces debt-service pressure and gives Sionna more capacity to fund research, manage setbacks, and pursue strategic options.
Read all positive factors
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$278.96M
Dividend YieldN/A
Average Volume (3M)433.16K
Price to Earnings (P/E)―
Beta (1Y)1.25
Revenue GrowthN/A
EPS Growth-26.18%
CountryUS
Employees59
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding45,212,400
10 Day Avg. Volume474,586
30 Day Avg. Volume433,158
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.17Price Target Upside145.81% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transm...
How the Company Makes Money
As a clinical-stage biotechnology company, Sionna Therapeutics’ ability to generate recurring commercial revenue from product sales is null (no marketed products publicly confirmed in the provided prompt). Its primary sources of cash typically con...
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -306.00K | -647.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -93.03M | -74.62M | -61.02M | -46.68M | -40.12M |
| Net Income | -97.38M | -75.27M | -61.69M | -47.26M | -40.24M |
Balance Sheet | |||||
| Total Assets | 283.25M | 325.95M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 211.03M | 235.88M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.07M | 8.68M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 17.47M | 19.12M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 265.77M | 306.83M | -163.71M | -114.88M | -69.92M |
Cash Flow | |||||
| Free Cash Flow | -98.05M | -66.67M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -97.76M | -66.30M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | 116.80M | -118.75M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 8.17M | 205.71M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Technical Analysis
Positive
6.17
Price Trends
32.75
Positive
26.82
Positive
Market Momentum
1.96
Negative
71.28
Negative
70.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SION, the sentiment is Positive. The current price of 6.17 is below the 20-day moving average (MA) of 37.46, below the 50-day MA of 32.75, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 1.96 indicates Negative momentum. The RSI at 71.28 is Negative, neither overbought nor oversold. The STOCH value of 70.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SION.
Sionna Therapeutics, Inc. Risk Analysis
Sionna Therapeutics, Inc. disclosed 76 risk factors in its most recent earnings report. Sionna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
anchored combination therapy for the treatment of cystic fibrosis, or experience significant delays in doing so, our business will be materially harmed. Q2, 2026
2.
agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. Q2, 2026
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $2.14B | -9.70 | -59.36% | ― | -86.20% | -476.63% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | $4.65B | -26.37 | -52.92% | ― | ― | 42.67% | |
54 Neutral | $2.06B | -14.99 | -9.96% | ― | -20.44% | -349.84% | |
51 Neutral | $1.85B | -3.90 | -57.79% | ― | 12.58% | 28.42% | |
44 Neutral | $3.12B | -37.17 | -7.70% | ― | 158.88% | 81.95% | |
42 Neutral | $278.96M | -2.78 | -32.94% | ― | ― | -26.18% |
* General Sector Average
SION
Sionna Therapeutics, Inc.
6.06
-19.66
-76.44%
SRPT
Sarepta Therapeutics
21.59
3.25
17.72%
NTLA
Intellia Therapeutics
13.11
1.51
13.02%
STOK
Stoke Therapeutics
32.59
12.82
64.85%
BEAM
Beam Therapeutics
30.48
13.63
80.89%
AMLX
Amylyx Pharmaceuticals Inc
37.18
27.76
294.69%
Sionna Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Sionna Reports Mixed Trial Results, Refocuses CF Pipeline
Negative
Aug 10, 2026
On August 10, 2026, Sionna Therapeutics reported topline results from its PreciSION CF Phase 2a trial of SION-719 added to Trikafta in cystic fibrosis patients, and from a Phase 1 trial of SION-451-based dual combinations in healthy volunteers. Th...
Executive/Board ChangesShareholder Meetings
Sionna Stockholders Reelect Directors, Ratify Deloitte as Auditor
Positive
Jun 18, 2026
At its June 17, 2026 Annual Meeting of Stockholders, Sionna Therapeutics, Inc. reported that a quorum was present, with 45,142,330 common shares outstanding as of the April 21, 2026 record date, and stockholders voted on the election of four Class...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.